Neogen Q1 Revenue Rises 6.5%; Raises FY27 Outlook

Neogen Chemicals (BOM:542665) reported Q2 2027 earnings, with a 42% revenue surge. The company guided FY27 battery chemicals revenue at INR 250-300 crore and FY28 at over INR 1,000 crore. Base chemicals guidance for FY27 was upgraded to over INR 1,100 crore. Net debt for FY28 is expected to be INR 1,300-1,500 crore. The company is benefiting from US demand shifts due to tax credits and has secured customer approvals for lithium electrolyte salts.

NEOGEN CORP (NEOG) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On March 2, 2026, Neogen Corporation (“ Neogen ”) announced that it had entered into a definitive agreement to sell its global Genomics business to Zoetis Inc. (“ Zoetis ”). This transaction is subject to customary closing conditions and regulatory approva

Neogen Chemicals (NSE: NEOGEN) reported Q2 FY27 earnings with a 144% YoY profit increase to INR 8 crore, beating EPS estimates but missing revenue forecasts. Revenue grew 42% to INR 296 crore, driven by a 585% surge in battery chemicals. The stock fell 3.5% post-results.

NEOG reported Q3 revenue of $222.8M, beating estimates by 7%, and adjusted EPS of $0.08, beating by 50%. Adjusted EBITDA was $41.6M, an 18.7% margin. The company raised FY revenue guidance to $887.5M and EBITDA to $182M. Management highlighted commercial execution gains, innovation investments, and operational efficiency improvements.

Neogen reported Q1 fiscal 2027 revenue of $222.8M, up 6.5%, with Food Safety and Animal Safety segments growing 7.4% and 4.2%, respectively. Gross margin improved to 47.4%. Adjusted net income rose to $17.5M. The company raised its fiscal 2027 revenue guidance to $885M-$890M and adjusted EBITDA guidance to $181M-$183M.

Neogen (NEOG) received an FDA warning over a contaminated veterinary product. The company's response and any follow-up actions will be key for investors to monitor. Additionally, investors should review the company's management structure and compensation packages.